Search results for "teriflunomide"

showing 5 items of 5 documents

Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.

2021

Objective: To identify baseline factors associated with disease activity in patients with relapsing–remitting multiple sclerosis (RRMS) under teriflunomide treatment. Methods: This was an independent, multi-centre, retrospective post-marketing study. We analysed data of 1,507 patients who started teriflunomide since October 2014 and were regularly followed in 28 Centres in Italy. We reported the proportions of patients who discontinued treatment (after excluding 32 lost to follow-up) and who experienced clinical disease activity, i.e., relapse(s) and/or confirmed disability worsening, as assessed by the Expanded Disability Status Scale (EDSS). Decision tree-based analysis was performed to i…

medicine.medical_specialtyNeurologyMultiple SclerosisToluidinesHydroxybutyratesOral drugsDiseaseRelapsing-RemittingSettore MED/26Pregnancy planning03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicineTeriflunomideTeriflunomideNitrilesmedicineHumans030212 general & internal medicineAdverse effectRetrospective StudiesExpanded Disability Status Scalebusiness.industryMultiple sclerosismedicine.diseaseSettore MED/26 - NEUROLOGIANeurologychemistryTolerabilityItalyMultiple sclerosis; Oral drugs; Teriflunomide; Crotonates; Humans; Hydroxybutyrates; Italy; Nitriles; Retrospective Studies; Toluidines; Multiple Sclerosis; Multiple Sclerosis Relapsing-RemittingCrotonatesNeurology (clinical)business030217 neurology & neurosurgeryJournal of neurology
researchProduct

Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience

2019

Teriflunomide (TRF) and Dimethyl fumarate (DMF) are licensed drugs for relapsing-remitting Multiple Sclerosis (RRMS). We aimed to compare the rate and the time to discontinuation among persons with RRMS (pwRRMS), newly treated with TRF and DMF. A retrospective study on prospectively collected data was performed in nine tertiary MS centers, in Italy. The 24-month discontinuation rate in the two cohorts was the primary study outcome. We also assessed the time to discontinuation and reasons of therapy withdrawn. Discontinuation of TRF and DMF was defined as a gap of treatment ≥ 60 days. A cohort of 903 pwRRMS (316 on TRF and 587 on DMF) was analyzed. During 24 months of follow-up, pwRRMS on TR…

Adultmedicine.medical_specialtyDiscontinuation rateTime FactorsToluidinesPopulationHydroxybutyratesRelapsing-RemittingDimethyl fumarateMultiple sclerosis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicineTeriflunomideNitrilesTeriflunomidemedicineHumansMultiple sclerosi030212 general & internal medicineeducationRetrospective Studieseducation.field_of_studyDimethyl fumaratebusiness.industryProportional hazards modelMultiple sclerosisDimethyl fumarate; Discontinuation rate; Multiple sclerosis; Real-life; Teriflunomide; Neurology; Neurology (clinical)Real-lifeRetrospective cohort studyMiddle Agedmedicine.diseaseDiscontinuationchemistryItalyNeurologyCrotonatesCohortDimethyl fumarate; Discontinuation rate; Multiple sclerosis; Real-life; Teriflunomide; Adult; Crotonates; Dimethyl Fumarate; Follow-Up Studies; Humans; Immunosuppressive Agents; Italy; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Retrospective Studies; Time Factors; ToluidinesNeurology (clinical)business030217 neurology & neurosurgeryImmunosuppressive AgentsFollow-Up Studies
researchProduct

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multi…

2018

BACKGROUND: The aim of the study was to evaluate the achievement of 'no evidence of disease activity' (NEDA) over a 12-month period in a large multicenter population with relapsing remitting multiple sclerosis (RRMS) treated with delayed-release dimethyl fumarate (DMF) and teriflunomide (TRF) using a propensity-score adjustment. METHODS: A time-to-event method was used to determine the percentages of patients with RRMS (pwRRMS) in both groups achieving NEDA 3 (no relapses, no 12-week confirmed disability progression, and no new T2/gadolinium-enhancing brain lesions). We described the safety profile of the investigated drugs. RESULTS: Of the 587 pwRRMS treated with DMF and the 316 pwRRMS tre…

safetymedicine.medical_specialtydimethyl fumarate; efficacy; no evidence of disease activity 3; safety; teriflunomide; pharmacology; neurology; neurology (clinical)Populationefficacylcsh:RC346-429Disease activity03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineTeriflunomideteriflunomideMedicine030212 general & internal medicineno evidence of disease activity 3educationlcsh:Neurology. Diseases of the nervous systemOriginal ResearchPharmacologyeducation.field_of_studydimethyl fumarateDimethyl fumaratebusiness.industryMultiple sclerosismedicine.diseasechemistryRelapsing remittingNeurologySettore MED/26 - NeurologiaReal wordNeurology (clinical)business030217 neurology & neurosurgerydimethyl fumarate; efficacy; no evidence of disease activity 3; safety; teriflunomide
researchProduct

Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current trea…

2018

Approved medications for relapsing-remitting multiple sclerosis have shown to be effective in terms of their anti-inflammatory potential. However, it is also crucial to evaluate what long-term effects a patient can expect from current MS drugs in terms of preventing neurodegeneration. Here we aim to provide an overview of the current treatment strategies in MS with a specific focus on potential neuroprotective effects. Areas covered: Randomized, double-blind and placebo or referral-drug controlled phase 2a/b and phase 3 trials were examined; non-blinded phase 4 studies (extension studies) were included to provide long-term data, if not otherwise available. Endpoints considered were expanded…

Oncologymedicine.medical_specialtyAnti-Inflammatory AgentsNeuroimagingDiseaseNeuropsychological TestsPlaceboNeuroprotectionDisability Evaluation03 medical and health scienceschemistry.chemical_compoundMultiple Sclerosis Relapsing-Remitting0302 clinical medicineInternal medicineTeriflunomidemedicineHumansPharmacology (medical)030212 general & internal medicineNeuronsExpanded Disability Status Scalebusiness.industryGeneral NeuroscienceMultiple sclerosismedicine.diseaseMagnetic Resonance ImagingFingolimodNeuroprotective AgentsTreatment OutcomeMultiple sclerosis functional compositechemistryDisease ProgressionNeurology (clinical)businessImmunosuppressive Agents030217 neurology & neurosurgerymedicine.drugExpert Review of Neurotherapeutics
researchProduct

Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis

2020

The introduction of oral disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) changed the therapeutic landscape and algorithms of RRMS treatment (1). In Europe, dimethyl fumarate (DMF) and teriflunomide (TRF) are approved as first-line agents and are often used as the initial therapeutic choice (2, 3). Pivotal trials showed the efficacy of both DMTs on controlling clinical relapses, disability accrual and magnetic resonance imaging (MRI) activity (4-8). Both DMTs had overall good tolerability. There have been no head-to-head randomized trials to compare these two DMTs; however, several real-world evidence (RWE) studies have compared DMF and TRF and provided u…

Cox models relapsing-remitting mul tiple sclerosis dimethyl fumarate teriflunomide
researchProduct